The Food and Drug Administration (FDA) said six cases in 6.8 million doses had been reported and it was acting “out of an abundance of caution”. Johnson & Johnson said it was also delaying vaccine rollout in Europe. The US move follows similar rare cases in the AstraZeneca vaccine, which has prompted some curbs in its use.
